BRIEF—Viridian seeks to raise funds through public offering

Massachusetts, USA-based biotech Viridian Therapeutics has submitted paperwork for a public offering of common and preferred stock.

The proceeds have been earmarked for further development of Viridian's clinical development programs, as well as for working capital and general corporate purposes.

The company is focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases.

Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.